central and peripheral glp-1 systems independently suppress eating The GLP-1: implications for food drug reward Glucagon-like Peptide-1 and the Central/Peripheral

Still, oral options will likely impact the market positively in terms of accessibility (an option for needle-phobic patients) and affordability

[13] [14] What dose will I get, and how often

US retailers that move early to tailor product ranges and merchandise their shelves targeting GLP-1 users may be better positioned to protect share as eating behaviors change. GlobalData projects that the GLP-1 pill market will grow from $3.2 billion in 2025 to $34.3 billion in 2031, with an annual CAGR of 48.4% over the six-year period

For more on weight-loss drugs, see our blog series.

This review describes the various -cell defects that appear in patients with diabetes and outline the mechanisms of -cell failure

Current Clinical Pharmacology, 12 (4), 253258